Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Diseases | 7 | 2025 | 373 | 3.110 |
Why?
|
| Thrombocytopenia | 9 | 2022 | 113 | 2.910 |
Why?
|
| Platelet Count | 5 | 2018 | 111 | 2.200 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 8 | 2022 | 216 | 1.280 |
Why?
|
| Indians, North American | 4 | 2025 | 534 | 1.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 5 | 2018 | 67 | 1.020 |
Why?
|
| Registries | 7 | 2015 | 393 | 0.910 |
Why?
|
| Health Education | 1 | 2025 | 75 | 0.900 |
Why?
|
| Vitamin D Deficiency | 1 | 2025 | 31 | 0.900 |
Why?
|
| Pregnancy | 7 | 2022 | 1219 | 0.840 |
Why?
|
| Dyslipidemias | 1 | 2024 | 32 | 0.830 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2024 | 48 | 0.820 |
Why?
|
| Vaccines | 1 | 2022 | 35 | 0.720 |
Why?
|
| Atherosclerosis | 1 | 2022 | 97 | 0.700 |
Why?
|
| Adolescent | 11 | 2025 | 3165 | 0.670 |
Why?
|
| Humans | 37 | 2025 | 28585 | 0.670 |
Why?
|
| Hemolytic-Uremic Syndrome | 3 | 2015 | 81 | 0.630 |
Why?
|
| ADAM Proteins | 4 | 2014 | 103 | 0.620 |
Why?
|
| Pregnancy Complications, Hematologic | 4 | 2021 | 38 | 0.600 |
Why?
|
| Thrombotic Microangiopathies | 2 | 2018 | 24 | 0.580 |
Why?
|
| Risk Factors | 8 | 2025 | 2111 | 0.580 |
Why?
|
| Young Adult | 10 | 2025 | 2804 | 0.580 |
Why?
|
| Adult | 15 | 2025 | 7922 | 0.570 |
Why?
|
| Placenta | 1 | 2018 | 78 | 0.560 |
Why?
|
| Female | 23 | 2025 | 15472 | 0.550 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 6 | 0.550 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 111 | 0.520 |
Why?
|
| Stroke | 3 | 2025 | 256 | 0.470 |
Why?
|
| Incidence | 3 | 2025 | 568 | 0.450 |
Why?
|
| Quinine | 1 | 2015 | 23 | 0.450 |
Why?
|
| United States | 8 | 2025 | 2201 | 0.390 |
Why?
|
| Aged | 7 | 2025 | 5525 | 0.380 |
Why?
|
| Male | 17 | 2025 | 13772 | 0.370 |
Why?
|
| Oklahoma | 6 | 2025 | 1038 | 0.360 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 3 | 2016 | 94 | 0.300 |
Why?
|
| Proportional Hazards Models | 3 | 2025 | 226 | 0.290 |
Why?
|
| Prevalence | 3 | 2025 | 510 | 0.270 |
Why?
|
| Blood Pressure | 2 | 2025 | 355 | 0.260 |
Why?
|
| Bone Marrow | 2 | 2025 | 81 | 0.250 |
Why?
|
| Focus Groups | 1 | 2025 | 101 | 0.230 |
Why?
|
| Middle Aged | 8 | 2025 | 7310 | 0.230 |
Why?
|
| Vitamin D | 1 | 2025 | 51 | 0.230 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2025 | 43 | 0.230 |
Why?
|
| Program Evaluation | 1 | 2025 | 172 | 0.220 |
Why?
|
| Depressive Disorder, Major | 2 | 2016 | 127 | 0.220 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 55 | 0.210 |
Why?
|
| Qualitative Research | 1 | 2025 | 200 | 0.210 |
Why?
|
| Models, Statistical | 1 | 2025 | 128 | 0.210 |
Why?
|
| Lipoproteins, LDL | 1 | 2024 | 36 | 0.210 |
Why?
|
| Child | 6 | 2022 | 2271 | 0.210 |
Why?
|
| Prospective Studies | 3 | 2024 | 1272 | 0.210 |
Why?
|
| Mass Screening | 1 | 2025 | 156 | 0.200 |
Why?
|
| Blood Platelets | 2 | 2018 | 206 | 0.200 |
Why?
|
| Child, Preschool | 3 | 2021 | 1167 | 0.190 |
Why?
|
| Cholesterol | 1 | 2024 | 202 | 0.190 |
Why?
|
| Antibodies | 2 | 2015 | 124 | 0.190 |
Why?
|
| Recurrence | 4 | 2022 | 325 | 0.190 |
Why?
|
| Snacks | 1 | 2021 | 5 | 0.180 |
Why?
|
| Myocardial Ischemia | 1 | 2022 | 73 | 0.180 |
Why?
|
| Lunch | 1 | 2021 | 10 | 0.180 |
Why?
|
| Food Preferences | 1 | 2021 | 21 | 0.180 |
Why?
|
| Vegetables | 1 | 2021 | 29 | 0.180 |
Why?
|
| Anemia, Hemolytic | 1 | 2021 | 22 | 0.180 |
Why?
|
| Attitude to Health | 1 | 2021 | 89 | 0.170 |
Why?
|
| ADAMTS13 Protein | 4 | 2014 | 126 | 0.170 |
Why?
|
| Feeding Behavior | 1 | 2021 | 103 | 0.170 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 351 | 0.160 |
Why?
|
| Songbirds | 1 | 2019 | 4 | 0.150 |
Why?
|
| Animal Migration | 1 | 2019 | 8 | 0.150 |
Why?
|
| Genetics, Population | 1 | 2019 | 72 | 0.150 |
Why?
|
| Chorionic Villi | 1 | 2018 | 7 | 0.150 |
Why?
|
| Blood Cell Count | 1 | 2018 | 15 | 0.150 |
Why?
|
| Blood Specimen Collection | 1 | 2018 | 14 | 0.150 |
Why?
|
| Capillaries | 1 | 2018 | 33 | 0.150 |
Why?
|
| Fetal Blood | 1 | 2018 | 40 | 0.150 |
Why?
|
| Mothers | 2 | 2016 | 124 | 0.140 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 402 | 0.140 |
Why?
|
| Reference Values | 1 | 2018 | 199 | 0.140 |
Why?
|
| Infant, Newborn | 3 | 2022 | 899 | 0.140 |
Why?
|
| Hemoglobins | 1 | 2018 | 118 | 0.140 |
Why?
|
| Blood Coagulation | 1 | 2018 | 120 | 0.140 |
Why?
|
| Postpartum Period | 1 | 2017 | 72 | 0.130 |
Why?
|
| Gestational Age | 1 | 2017 | 146 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 42 | 0.130 |
Why?
|
| Rituximab | 2 | 2014 | 64 | 0.130 |
Why?
|
| Adaptation, Physiological | 1 | 2017 | 173 | 0.120 |
Why?
|
| Psychological Tests | 1 | 2016 | 21 | 0.120 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2016 | 28 | 0.120 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 98 | 0.120 |
Why?
|
| Autoantibodies | 1 | 2018 | 479 | 0.120 |
Why?
|
| Infant | 2 | 2022 | 1019 | 0.120 |
Why?
|
| Pentostatin | 1 | 2015 | 4 | 0.120 |
Why?
|
| Wisconsin | 1 | 2015 | 9 | 0.120 |
Why?
|
| Organoplatinum Compounds | 1 | 2015 | 24 | 0.110 |
Why?
|
| Ambulatory Care Facilities | 1 | 2015 | 54 | 0.110 |
Why?
|
| Back Pain | 1 | 2014 | 21 | 0.110 |
Why?
|
| Vancomycin | 1 | 2015 | 58 | 0.110 |
Why?
|
| Deoxycytidine | 1 | 2015 | 65 | 0.110 |
Why?
|
| Dopamine | 1 | 2014 | 22 | 0.110 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2014 | 13 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 32 | 0.110 |
Why?
|
| Hypotension | 1 | 2014 | 19 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2013 | 265 | 0.110 |
Why?
|
| Necrosis | 1 | 2014 | 85 | 0.110 |
Why?
|
| Albuminuria | 1 | 2014 | 23 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 534 | 0.110 |
Why?
|
| Depression | 1 | 2016 | 222 | 0.110 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 42 | 0.110 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2014 | 7 | 0.110 |
Why?
|
| Pre-Eclampsia | 1 | 2014 | 49 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 73 | 0.100 |
Why?
|
| Recovery of Function | 1 | 2014 | 122 | 0.100 |
Why?
|
| Japan | 1 | 2013 | 23 | 0.100 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 20 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2013 | 50 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2014 | 173 | 0.090 |
Why?
|
| Sex Factors | 1 | 2013 | 467 | 0.090 |
Why?
|
| Age Factors | 1 | 2013 | 734 | 0.090 |
Why?
|
| Fatigue | 1 | 2011 | 64 | 0.080 |
Why?
|
| Methods | 1 | 2010 | 27 | 0.080 |
Why?
|
| Cause of Death | 2 | 2025 | 73 | 0.080 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2010 | 14 | 0.080 |
Why?
|
| Data Mining | 1 | 2010 | 15 | 0.080 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 45 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 1 | 2010 | 48 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2025 | 524 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2014 | 631 | 0.080 |
Why?
|
| Morbidity | 2 | 2022 | 58 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2016 | 893 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 1026 | 0.060 |
Why?
|
| Retrospective Studies | 1 | 2013 | 2612 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2013 | 992 | 0.060 |
Why?
|
| Induction Chemotherapy | 1 | 2025 | 11 | 0.060 |
Why?
|
| Remission Induction | 1 | 2025 | 58 | 0.060 |
Why?
|
| Blood Pressure Determination | 1 | 2025 | 27 | 0.060 |
Why?
|
| Community-Based Participatory Research | 1 | 2025 | 37 | 0.060 |
Why?
|
| Social Determinants of Health | 1 | 2025 | 37 | 0.060 |
Why?
|
| Telomere | 1 | 2025 | 36 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2025 | 126 | 0.060 |
Why?
|
| American Heart Association | 1 | 2024 | 21 | 0.050 |
Why?
|
| Machine Learning | 1 | 2025 | 91 | 0.050 |
Why?
|
| Goals | 1 | 2024 | 34 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 994 | 0.050 |
Why?
|
| Vitamin K | 1 | 2022 | 39 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2022 | 2402 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 70 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2022 | 190 | 0.050 |
Why?
|
| Plasma | 1 | 2022 | 32 | 0.050 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2021 | 21 | 0.050 |
Why?
|
| Child Day Care Centers | 1 | 2021 | 25 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2022 | 191 | 0.040 |
Why?
|
| Disease Management | 1 | 2021 | 90 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 265 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 295 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 244 | 0.040 |
Why?
|
| Louisiana | 1 | 2019 | 6 | 0.040 |
Why?
|
| North Carolina | 1 | 2019 | 17 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2019 | 51 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2018 | 6 | 0.040 |
Why?
|
| Trimethoprim | 1 | 2018 | 6 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2019 | 125 | 0.040 |
Why?
|
| Flavonoids | 1 | 2018 | 32 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 16 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2018 | 18 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2018 | 63 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2018 | 20 | 0.040 |
Why?
|
| Influenza Vaccines | 1 | 2018 | 51 | 0.040 |
Why?
|
| Proteasome Inhibitors | 1 | 2018 | 26 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2019 | 245 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 117 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 550 | 0.030 |
Why?
|
| Peripartum Period | 1 | 2016 | 5 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 782 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 100 | 0.030 |
Why?
|
| Depression, Postpartum | 1 | 2016 | 15 | 0.030 |
Why?
|
| Animals | 2 | 2019 | 10583 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2014 | 19 | 0.030 |
Why?
|
| Dobutamine | 1 | 2014 | 7 | 0.030 |
Why?
|
| Catecholamines | 1 | 2014 | 18 | 0.030 |
Why?
|
| Ligation | 1 | 2014 | 39 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 72 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2014 | 67 | 0.030 |
Why?
|
| Cardiotonic Agents | 1 | 2014 | 28 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2014 | 42 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 75 | 0.030 |
Why?
|
| Echocardiography | 1 | 2014 | 108 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2014 | 48 | 0.030 |
Why?
|
| Plasma Exchange | 1 | 2014 | 104 | 0.030 |
Why?
|
| Review Literature as Topic | 1 | 2014 | 10 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2013 | 19 | 0.030 |
Why?
|
| Mortality | 1 | 2013 | 46 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2014 | 144 | 0.030 |
Why?
|
| Internationality | 1 | 2013 | 31 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 267 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2014 | 131 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 431 | 0.020 |
Why?
|
| Filgrastim | 1 | 2011 | 7 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 2011 | 15 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2011 | 18 | 0.020 |
Why?
|
| United Kingdom | 1 | 2011 | 77 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 302 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 415 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 988 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 2045 | 0.020 |
Why?
|